Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Nutritional Interventions in the Care Plan for Cancer Patients: The NOA Project.
García-Luna PP, Rabat Restrepo JM, Muñoz-Ayllón M, de la Calle Gil M, Remón P, Sánchez-Torralvo FJ, Pachón J, García-González JJ, García-Manrique T, Salvador-Bofill J, Vicente D, Olveira G. García-Luna PP, et al. Among authors: salvador bofill j. Nutrients. 2023 Jan 6;15(2):292. doi: 10.3390/nu15020292. Nutrients. 2023. PMID: 36678163 Free PMC article.
[Analysis of nutritional interventions in the care process of oncological patients in Andalusia - The NOA project].
García Luna PP, Calañas Continente A, Villarrubia Pozo A, Jiménez Lorente CP, Vicente Baz D, Castanedo OI, Salvador Bofill J, Rabat Restrepo JM, Díaz Gómez L, Mediano Rambla MD, Brozeta Benítez T, Muñoz Lucero T, Olveira G. García Luna PP, et al. Among authors: salvador bofill j. Nutr Hosp. 2021 Jul 29;38(4):758-764. doi: 10.20960/nh.03444. Nutr Hosp. 2021. PMID: 33703912 Free article. Spanish.
Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.
Miras I, Gil A, Benavent M, Castilla MÁ, Vieites B, Dominguez-Cejudo MÁ, Molina-Pinelo S, Alfaro L, Frutos J, Ruiz-Borrego M, Falcón A, Cejuela M, Salvador-Bofill J. Miras I, et al. Among authors: salvador bofill j. Ther Adv Med Oncol. 2024 Dec 23;16:17588359241309169. doi: 10.1177/17588359241309169. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39734711 Free PMC article.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
Cejuela M, Gil-Torralvo A, Castilla MÁ, Domínguez-Cejudo MÁ, Falcón A, Benavent M, Molina-Pinelo S, Ruiz-Borrego M, Salvador Bofill J. Cejuela M, et al. Among authors: salvador bofill j. Int J Mol Sci. 2023 May 9;24(10):8488. doi: 10.3390/ijms24108488. Int J Mol Sci. 2023. PMID: 37239834 Free PMC article.
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Salvador Bofill J, Moreno Anton F, Rodriguez Sanchez CA, Galve Calvo E, Hernando Melia C, Ciruelos Gil EM, Vidal M, Jiménez-Rodriguez B, De la Cruz Merino L, Martínez Jañez N, Villanueva Vazquez R, de Toro Salas R, Anton Torres A, Alvarez Lopez IM, Gavila Gregori J, Quiroga Garcia V, Vicente Rubio E, De la Haba-Rodriguez J, Gonzalez-Santiago S, Diaz Fernandez N, Barnadas Molins A, Cantos Sanchez de Ibargüen B, Delgado Mingorance JI, Bellet Ezquerra M, de Casa S, Gimeno A, Martin M. Salvador Bofill J, et al. Breast. 2022 Dec;66:77-84. doi: 10.1016/j.breast.2022.09.006. Epub 2022 Sep 28. Breast. 2022. PMID: 36206609 Free PMC article. Clinical Trial.
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Cottu P, Ring A, Abdel-Razeq H, Marchetti P, Cardoso F, Salvador Bofill J, Martín M, Menon-Singh L, Wu J, De Laurentiis M. Cottu P, et al. Among authors: salvador bofill j. Breast. 2022 Apr;62:75-83. doi: 10.1016/j.breast.2022.01.016. Epub 2022 Jan 31. Breast. 2022. PMID: 35131646 Free PMC article. Clinical Trial.
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists.
Sánchez-Rovira P, Zamora P, Salvador-Bofill J, Morales S, Martínez-Jáñez N, Martínez-de-Dueñas E, Lluch A, Illarramendi JJ, Gómez-Pardo P, Gavilá Gregori J, García-Palomo A, García-Mata J, Fernández Y, Del Barco S, de Juan A, Ciruelos E, Chacón JI, Calvo L, Barnadas A, Albanell J. Sánchez-Rovira P, et al. Among authors: salvador bofill j. J Drug Assess. 2019 Apr 8;8(1):62-69. doi: 10.1080/21556660.2019.1604375. eCollection 2019. J Drug Assess. 2019. PMID: 31069129 Free PMC article.
12 results